According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “
Several other research firms also recently weighed in on SELB. Canaccord Genuity set a $40.00 price target on shares of Mallinckrodt and gave the company a buy rating in a research note on Monday, March 18th. ValuEngine downgraded shares of Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd. Mizuho set a $88.00 price target on shares of Gilead Sciences and gave the company a buy rating in a research note on Friday, May 10th. Finally, Stifel Nicolaus reaffirmed a buy rating and set a $7.00 price target on shares of Selecta Biosciences in a research note on Friday, March 15th. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. Selecta Biosciences currently has an average rating of Hold and an average target price of $8.04.
Selecta Biosciences (NASDAQ:SELB) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.06. The firm had revenue of $0.01 million during the quarter. As a group, research analysts expect that Selecta Biosciences will post -1.35 earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the company. Two Sigma Investments LP raised its stake in shares of Selecta Biosciences by 87.8% during the fourth quarter. Two Sigma Investments LP now owns 200,498 shares of the company’s stock valued at $533,000 after acquiring an additional 93,719 shares in the last quarter. Two Sigma Advisers LP raised its stake in Selecta Biosciences by 18.3% in the fourth quarter. Two Sigma Advisers LP now owns 54,900 shares of the company’s stock worth $146,000 after buying an additional 8,500 shares in the last quarter. Polaris Venture Management Co. V L.L.C. raised its stake in Selecta Biosciences by 72.6% in the first quarter. Polaris Venture Management Co. V L.L.C. now owns 2,773,479 shares of the company’s stock worth $6,573,000 after buying an additional 1,166,666 shares in the last quarter. FMR LLC raised its stake in Selecta Biosciences by 23.5% in the fourth quarter. FMR LLC now owns 345,046 shares of the company’s stock worth $918,000 after buying an additional 65,623 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Selecta Biosciences by 17.9% in the fourth quarter. Geode Capital Management LLC now owns 175,308 shares of the company’s stock worth $466,000 after buying an additional 26,568 shares in the last quarter. 47.07% of the stock is owned by hedge funds and other institutional investors.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.